AzTrials
AzTrials

HIVNCT04549259

Multi-Component Intervention to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV

A study testing Group-Based Social Support, HIV Stigma Reduction and Strengths-Based Case Management (SBCM) in people with HIV, run by Medical College of Wisconsin at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Engagement in HIV medical care and adherence to HIV medications are both essential in improving health outcomes among people living with HIV (PLH), but PLH living in rural areas-who suffer higher mortality rates than their urban counterparts-can confront multiple barriers to care engagement and adherence, especially… Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
HIV
What is being tested?
Group-Based Social Support, HIV Stigma Reduction and Strengths-Based Case Management (SBCM)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
61 participants
Where
1 siteUnited States
Study dates
14 Apr 2021to 9 May 2022
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 50 years or greater
  • Living in a zip code classified as a "Small and Isolated Small Rural Town" area by Rural-Urban Commuting Area Codes (RUCAs), and/or in a county classified as rural based on RUCAs, and/or in a county with a score of .4 or higher on the index of relative rurality (IRR)
  • Living in Alabama, Arkansas, Georgia, Kentucky, Mississippi, Missouri, Oklahoma, South Carolina, or Tennessee
  • Living with HIV
  • Indicates willingness to participate in support groups
  • Indicates willingness to self-collect a dried blood spot sample
  • Has a telephone at home
  • Able to provide informed consent

Who cannot join

  • Not meeting eligibility criteria described above

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Center for AIDS Intervention Research, Medical College of Wisconsin

    Milwaukee, Wisconsin, 53202

Other trials in United States

About this study

Official title: Testing a Multi-Component Intervention to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV

Engagement in HIV medical care and adherence to HIV medications are both essential in improving health outcomes among people living with HIV (PLH), but PLH living in rural areas-who suffer higher mortality rates than their urban counterparts-can confront multiple barriers to care engagement and adherence, especially as they face the logistical, medical, and social challenges associated with aging. This project will pilot test four intervention components designed to improve care engagement and medication adherence to determine their impact on health outcomes and quality of life among rural, older PLH. The four intervention components, adapted from evidence-based interventions and delivered remotely, are: (1) counselor-facilitated peer social support, (2) HIV stigma reduction, (3) strengths-based case management, and (4) individually-tailored technology use optimization. The investigators hypothesize that components will be acceptable to participants, will be feasible to administer remotely, and will show preliminary impact on (1) the proportion of participants that have viral suppression and (2) health-related quality of life. Results from this study will provide us with tools to improve health outcomes for rural older people living with HIV.

Conditions
HIV
Being tested
Group-Based Social Support, HIV Stigma Reduction, Strengths-Based Case Management (SBCM), Personalized Technology Detailing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Group-Based Social SupportBehavioural

    This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 8 consecutive weeks. The calls will last approximately 90 minutes and will include 5-8 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Therapists will facilitate mutual support among group members, encourage greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy (Heckman et al., 2013).

  • HIV Stigma ReductionBehavioural

    This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 6 consecutive weeks. The calls will last approximately 60-90 minutes and will include 5-8 individuals per group. This intervention is grounded in minority stress theory and will use cognitive-behavioral strategies to help empower participants to cope with stressful and stigmatizing experiences. Intervention components may include minimizing self-stigmatizing attitudes, reducing engulfment, developing a sense of future and hope, and developing and pursuing meaningful life goals. This intervention is an adaptation of "Ending Self Stigma" (Lucksted et al., 2011).

  • Strengths-Based Case Management (SBCM)Behavioural

    The investigators have adapted an individually-tailored strengths-based case management (SBCM) intervention to help address the multiple structural barriers faced by rural older PLH. The adapted intervention, delivered by trained research staff, will include two 60-minute telephone-based SBCM counseling sessions with shorter follow-up phone calls to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.

  • Personalized Technology DetailingBehavioural

    Participants will be called by a technology-fluent study staff member, who will assess the current state of their technology literacy, access, and use. Detailing will focus on advancing the participant along the technology use cascade (using the internet, possessing a device and service to access internet at home, using the internet to access their electronic health record and pharmacy services, seeking HIV-related information, and finding social support). Each participant will be provided with personalized assistance based on their local and personal circumstances. Because of the individualized advice provided, there will be a range of contacts between 1 and 5, at customized intervals. Detailing protocols include the option of providing the participant with a tablet including cellular service (for 3 months) when in-home internet service is not available or is cost prohibitive.

Study groups in NCT04549259
Study groupRoleWhat they receive
Social Support + Stigma Reduction + SBCM + Tech DetailingExperimentalNot described
Receives: Behavioral: Group-Based Social Support; Behavioral: HIV Stigma Reduction; Behavioral: Strengths-Based Case Management (SBCM); Behavioral: Personalized Technology Detailing
Social Support + Stigma Reduction + SBCMExperimentalNot described
Receives: Behavioral: Group-Based Social Support; Behavioral: HIV Stigma Reduction; Behavioral: Strengths-Based Case Management (SBCM)
Social Support + Stigma Reduction + Technology DetailingExperimentalNot described
Receives: Behavioral: Group-Based Social Support; Behavioral: HIV Stigma Reduction; Behavioral: Personalized Technology Detailing
Social Support + Stigma ReductionExperimentalNot described
Receives: Behavioral: Group-Based Social Support; Behavioral: HIV Stigma Reduction
Social Support + SBCM + Technology DetailingExperimentalNot described
Receives: Behavioral: Group-Based Social Support; Behavioral: Strengths-Based Case Management (SBCM); Behavioral: Personalized Technology Detailing
Social Support + SBCMExperimentalNot described
Receives: Behavioral: Group-Based Social Support; Behavioral: Strengths-Based Case Management (SBCM)
Social Support + Technology DetailingExperimentalNot described
Receives: Behavioral: Group-Based Social Support; Behavioral: Personalized Technology Detailing
Social SupportExperimentalNot described
Receives: Behavioral: Group-Based Social Support
Stigma Reduction + SBCM + Technology DetailingExperimentalNot described
Receives: Behavioral: HIV Stigma Reduction; Behavioral: Strengths-Based Case Management (SBCM); Behavioral: Personalized Technology Detailing
Stigma Reduction + SBCMExperimentalNot described
Receives: Behavioral: HIV Stigma Reduction; Behavioral: Strengths-Based Case Management (SBCM)
Stigma Reduction + Technology DetailingExperimentalNot described
Receives: Behavioral: HIV Stigma Reduction; Behavioral: Personalized Technology Detailing
Stigma ReductionExperimentalNot described
Receives: Behavioral: HIV Stigma Reduction
SBCM + Technology DetailingExperimentalNot described
Receives: Behavioral: Strengths-Based Case Management (SBCM); Behavioral: Personalized Technology Detailing
SBCMExperimentalNot described
Receives: Behavioral: Strengths-Based Case Management (SBCM)
Technology DetailingExperimentalNot described
Receives: Behavioral: Personalized Technology Detailing
HIV Information OnlyNo interventionThis arm will not receive any of the 4 intervention components but will receive information on successfully aging with HIV.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of Participants With HIV Viral Load ≥832 Copies/mL (HemaSpot DBS)

    Proportion of participants with HIV viral load ≥832 copies/mL, as measured through use of HemaSpot dried blood spot (DBS) testing. At baseline and follow-up, participants were sent dried blood spot (DBS) kits by mail to complete self-collection of blood samples for HIV viral load testing. Following specimen collection, participants placed the filled HemaSpot container into the shipping envelope, which sent the specimen directly to the clinical laboratory for testing. HemaSpot devices with sufficient blood volume were tested using Abbott m2000 RealTime HIV-1 dried blood spot (DBS) quantitative assay, with 832 copies/mL limit of detection. DBS viral load results were classified in three categories: 1. Detected and quantifiable at ≥832 copies/mL; 2. Detected and non-quantifiable, estimated between <832 and >300 copies/mL; and 3. Not detected, estimated to be <300 copies/mL.

    Measured: 3 months following enrollment/baseline survey

  2. Health-Related Quality of Life

    Based on full scale scores from the 31-item WHOQOL-HIV BREF (O'Connell \& Skevington, 2012), with scores ranging from 0 to 100. Higher scores indicate higher (better) quality of life.

    Quality of life was assessed with 31 items from the WHOQOL-HIV BREF (O'Connell \& Skevington, 2012). Domains assessed include physical health; psychological health; level of independence; social relationships; environmental health; and personal beliefs. Additionally, two individual items focus on overall quality of life and general health. Domain scores were created as described by the WHO, and we created a composite quality of life score by equally weighting the 6 domains, overall quality of life item, and general health item. The composite score was rescaled such that overall scores ranged from 0 to 100, with higher scores indicating better health-related quality of life.

    Measured: 3 months following enrollment/baseline survey

Secondary outcomes (2)
  1. Medication Adherence

    Adherence to HIV antiretroviral medications in the past 30 days was assessed with the 3 items from the Wilson adherence scale (Wilson et al., 2017; αs = .71-.79). This scale was scored in line with Wilson et al., with scores ranging from 0 to 100 and higher scores indicating better adherence. Due to significant skew in this outcome, we created a binary variable indicating perfect adherence to HIV medications.

    Measured: 3 months following enrollment/baseline survey

  2. Depressive Symptoms

    Depressive symptoms during the past 2 weeks were assessed with the 9 items from the Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001; αs = .87-.90). Participants indicated how often they had experienced different depressive symptoms (e.g., "Feeling down, depressed, or hopeless"). Responses ranged from not at all (0) to nearly every day (3). Items were summed to yield scores ranging from 0 to 27, with higher scores indicating more depressive symptoms.

    Measured: 3 months following enrollment/baseline survey

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Sep 2020
  2. Study start14 Apr 2021
  3. Primary completion9 May 2022
  4. Study completion9 May 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Masking
None (open label)
Enrolment
61 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04549259
Sponsor's protocol ID
R56NR019443
Status last verified
Jun 2023
First submitted
1 Sep 2020
Last updated
12 Jul 2023
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a New Three-Item Self-Report Measure for Medication Adherence. AIDS Behav. 2016 Nov;20(11):2700-2708. doi: 10.1007/s10461-016-1406-x.

    PubMed 27098408
  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.

    PubMed 11556941
  • O'Connell KA, Skevington SM. An international quality of life instrument to assess wellbeing in adults who are HIV-positive: a short form of the WHOQOL-HIV (31 items). AIDS Behav. 2012 Feb;16(2):452-60. doi: 10.1007/s10461-010-9863-0.

    PubMed 21181253

Questions about this trial

What is this clinical trial studying?

A study testing Group-Based Social Support, HIV Stigma Reduction and Strengths-Based Case Management (SBCM) in people with HIV, run by Medical College of Wisconsin at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 12 Jul 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of Participants With HIV Viral Load ≥832 Copies/mL (HemaSpot DBS) (time frame: 3 months following enrollment/baseline survey). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04549259, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in